Petros Grivas

University of Washington
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

A and B, Representative micrographs of HER2 IHC staining in prostate cancer ( A ) and urothelial cancer ( B ) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate ( E ) and urothelial ( F ) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.

Year:

2025

A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in ( A ) prostate cancer and ( B ) urothelial cancer.

Year:

2025

HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort ( n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression ( P = 0.2). In urothelial carcinoma ( n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.

Year:

2025

A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in ( A ) prostate and ( B ) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with ( C ) prostate and ( D ) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.

Year:

2025

Response to immune checkpoint inhibitors (ICIs) is associated with several biological pathways, including tumor immunogenicity and antitumor immunity. Identifying host factors involved in these pathways may guide personalized ICI treatment. We describe the application of chromatin conformation assays to blood from patients with advanced urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial (NCT02603432). This trial demonstrated a significant survival benefit with avelumab maintenance plus best supportive care (BSC) vs BSC alone following non-progression with platinum-based chemotherapy as first-line therapy. Blood-based chromatin conformation markers (CCMs) were screened for associations with high/low immune effector gene expression in tumors and for interactions with outcomes and tumor mutation burden. Candidate CCMs included genes involved in several immune response pathways, such as POU2F2, which encodes a transcription factor that regulates B-cell maturation. Our findings suggest that polygenic host factors may affect response to ICIs and support further investigation of chromatin conformation assays.

Year:

2025

Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer histology. Although many therapies are now approved for the treatment of cancers harboring specific genomic alterations, most patients do not respond to therapies targeting a single alteration. Further, when antitumor responses do occur, they are often not durable due to the development of drug resistance. Therefore, there is a great need to identify rational combination therapies that may be more effective. To address this need, the NCI and National Clinical Trials Network have developed NCI-ComboMATCH, the successor to NCI-MATCH. Like the original trial, NCI-ComboMATCH is a signal-seeking study. The goal of ComboMATCH is to overcome drug resistance to single-agent therapy and/or utilize novel synergies to increase efficacy by developing genomically-directed combination therapies, supported by strong preclinical in vivo evidence. Although NCI-MATCH was mainly comprised of multiple single-arm studies, NCI-ComboMATCH tests combination therapy, evaluating both combination of targeted agents as well as combinations of targeted therapy with chemotherapy. Although NCI-MATCH was histology agnostic with selected tumor exclusions, ComboMATCH has histology-specific and histology-agnostic arms. Although NCI-MATCH consisted of single-arm studies, ComboMATCH utilizes single-arm as well as randomized designs. NCI-MATCH had a separate, parallel Pediatric MATCH trial, whereas ComboMATCH will include children within the same trial. We present rationale, scientific principles, study design, and logistics supporting the ComboMATCH study.

Year:

2025

PURPOSE Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder (UBC). Limited data on N4 positivity in nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate N4 positivity among GU malignancies. METHODS A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Protocol was amended to incorporate a new updated search on March 2024. RESULTS Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma (UTUC), six on histologic subtypes (HS) and divergent histology of the bladder, one on papillary renal cell carcinoma (pRCC), one in chromophobe RCC (chRCC), two on penile cancer, one in prostate cancer (PCa). Among UBC, stratifying per stage N4 positivity was higher in metastatic (weighted mean [WM], 90.8; range, 59.6-100) and in non–muscle-invasive (WM, 87.4; range, 86.7-88.3) than in muscle-invasive UC (WM, 83.1; range, 68.2-100). The N4 positivity of UBC was higher than UTUC (WM, 62.9; range, 44.4-65.7). Immunohistochemistry N4 positivity was reported to be lower in non-UC malignancies, including pRCC (WM, 44.1; range, 44.1-44.1), HS (WM, 63.5; range, 0-100), PCa (WM0; range, 0-0), chRCC (WM, 18.5; range, 18.5-18.5), and penile cancer (WM, 86.5; range, 61.4-98.3), compared with UBC overall (WM, 87.1; range, 59.6-100). CONCLUSION Non-UC malignancies seem to have a lower N4 positivity rate than UC. N4 positivity in bladder cancer appears to vary according to stage and presence of HS. The predictive and prognostic role of N4 must be further characterized in larger and prospective studies.

Year:

2024

Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid tumors harboring a functional FGFR1–3 fusion. Patients and Methods: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. Results: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. Conclusions: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549

Year:

2024

Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2–directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1–3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression. Patients and Methods: TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1–3 were analyzed for Trop-2 membrane expression by considering histological scores (H-scores; scale 0–300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated. Results: In C1–3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H-score was 215 (180–246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80–98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels. Conclusions: Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels.

Year:

2024

Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2–directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1–3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression. Patients and Methods: TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1–3 were analyzed for Trop-2 membrane expression by considering histological scores ( H -scores; scale 0–300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated. Results: In C1–3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H -score was 215 (180–246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80–98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels. Conclusions: Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (53)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Hyun Jung Lee

Assistant Professor

Pusan National University Yangsan Hospital

SOUTH KOREA
View details

Julia Glade Bender

Vice Chair for Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Douglas Hawkins

Professor

University of Washington

UNITED STATES
View details

Suzanne George

Harvard University

UNITED STATES
View details

Phillip Palmbos

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

Andrea Salonia

Dean of the Studies

Vita-Salute San Raffaele University

ITALY
View details

Andrew C. Hsieh

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Nancy Chan

Assistant Professor

NYU School of Medicine

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

James Harding

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Elad Sharon

Associate Professor

Harvard University

UNITED STATES
View details

Lawrence True

Professor

University of Washington

UNITED STATES
View details

Gavin Ha

Associate Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

jordan Berlin

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Andrea Necchi

Associate Professor

Vita-Salute San Raffaele University

ITALY
View details

Umang Swami

University of Utah

UNITED STATES
View details

Joshua J. Meeks

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

James Ford

Professor

Stanford University

UNITED STATES
View details

Michael Haffner

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Lipika Goyal

Director of Gastrointestinal Oncology

Stanford University

UNITED STATES
View details

Andrés Cervantes

Professor of Medicine

University of Valencia

SPAIN
View details

Gary Lyman

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Nancy Davis

Associate Professor of Medicine & Urology

Vanderbilt University Medical Center

UNITED STATES
View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES
View details

Sonali Arora

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Heather H. Cheng

Professor

University of Washington

UNITED STATES
View details

Radhika A Patel

Fred Hutch Cancer Center

UNITED STATES
View details

Ashish Kamat

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Evan Y. Yu

University of Washington

UNITED STATES
View details

Jin Won Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Colm Morrissey

Research Professor

University of Washington

UNITED STATES
View details

Yohann Loriot

Institut Gustave Roussy

FRANCE
View details

Razelle Kurzrock

-

UNITED STATES
View details

Elena Garralda

Director

-

SPAIN
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael T. Schweizer

University of Washington

UNITED STATES
View details

Ingo Mellinghoff

Department Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Bruce Montgomery

University of Washington

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details

srikala sridhar

University Health Network

CANADA
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Nataliya Uboha

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

Maria Tretiakova

Professor

University of Washington

UNITED STATES
View details

Daniel P. Petrylak

-

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jessica Hawley

Assistant Professor

University of Washington

UNITED STATES
View details

Do-Youn Oh

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Omar Alhalabi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details